{"product_id":"sarepta-business-model-canvas","title":"Sarepta Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta's Biotech Business Model Unveiled!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Sarepta Therapeutics's business model. This in-depth Business Model Canvas reveals how the company drives value through its innovative gene therapies for rare diseases, captures market share by focusing on specific patient populations, and stays ahead in a competitive landscape through strategic partnerships and robust R\u0026amp;D. Ideal for entrepreneurs, consultants, and investors looking for actionable insights into a leading biotech firm.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Academia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics actively partners with prestigious research institutions and academic centers, including Nationwide Children's Hospital, Columbia University, Harvard University, the University of Florida College of Medicine, and the University of Western Australia. These collaborations are fundamental to deepening scientific insights and driving progress in drug discovery and early-stage development for rare genetic disorders like Duchenne muscular dystrophy and limb-girdle muscular dystrophies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology and Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics heavily relies on strategic alliances with other biotechnology and pharmaceutical companies to broaden its product pipeline and utilize shared technological strengths. A prime example is its collaboration with Arrowhead Pharmaceuticals, which grants Sarepta access to cutting-edge RNA interference (RNAi) programs targeting a range of rare genetic disorders.\u003c\/p\u003e\n\u003cp\u003eThis partnership with Arrowhead Pharmaceuticals, announced in 2021 and extended through 2024, is a key driver for Sarepta's diversification strategy and its pursuit of future growth avenues. The deal allows Sarepta to explore new therapeutic modalities beyond its core gene therapy focus, potentially accelerating the development of novel treatments for underserved patient populations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations (CMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics relies heavily on Contract Manufacturing Organizations (CMOs) to produce its complex gene therapies and precision genetic medicines. These partnerships are crucial for ensuring both the capacity and specialized expertise needed to manufacture clinical trial materials and commercial drug supplies.  For instance, in 2023, Sarepta continued to expand its manufacturing capabilities, including through CMO relationships, to meet growing demand for its Duchenne muscular dystrophy therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics cultivates vital relationships with patient advocacy groups, including organizations like Asociación Distrofia Muscular and GFB Onlus. These partnerships are crucial for driving early genetic testing initiatives and amplifying disease awareness across global patient communities.\u003c\/p\u003e\n\u003cp\u003eThese collaborations enable Sarepta to gain deep insights into the evolving needs of patients and their families. This understanding is fundamental in their efforts to improve treatment accessibility and streamline participation in clinical trials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisease Awareness:\u003c\/strong\u003e Partnerships help raise public and medical understanding of rare neuromuscular diseases.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGenetic Testing:\u003c\/strong\u003e Advocacy groups often champion early genetic testing, which is critical for timely diagnosis and treatment initiation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Support:\u003c\/strong\u003e These organizations provide essential resources, emotional support, and community for patients and caregivers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Trial Recruitment:\u003c\/strong\u003e Advocacy groups play a key role in informing patients about and encouraging participation in clinical trials, accelerating drug development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta's business model heavily relies on collaborations with healthcare providers and specialized treatment centers. These partnerships are crucial for the effective administration of its gene therapies, which often require specialized handling and patient monitoring. For instance, in 2024, Sarepta continued to expand its network of treatment centers to ensure broad access for patients with Duchenne muscular dystrophy (DMD).\u003c\/p\u003e\n\u003cp\u003eThese collaborations are vital for the successful delivery of Sarepta's approved products, such as Elevidys (delandistrogene moxeparvovec), to eligible patients. The centers provide the necessary infrastructure and trained personnel for infusion and follow-up care, ensuring optimal treatment outcomes and patient safety. This network is essential for scaling the delivery of these complex therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHospital and Clinic Networks\u003c\/strong\u003e: Sarepta partners with leading hospitals and specialized clinics across the United States and Europe.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialized Treatment Centers\u003c\/strong\u003e: Collaborations include centers with expertise in rare genetic diseases and gene therapy administration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Access Programs\u003c\/strong\u003e: These partnerships facilitate patient identification, enrollment, and access to Sarepta's therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReal-World Evidence Generation\u003c\/strong\u003e: Collaborating centers contribute to the collection of real-world data, supporting ongoing research and product development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Gene Therapy and Rare Disease Progress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics' key partnerships extend to contract manufacturing organizations (CMOs) critical for producing its complex gene therapies. In 2023, Sarepta continued to leverage these relationships to scale manufacturing, ensuring supply for its Duchenne muscular dystrophy (DMD) therapies and meeting growing demand.\u003c\/p\u003e\n\u003cp\u003eFurthermore, collaborations with academic institutions like Nationwide Children's Hospital and Harvard University are vital for advancing scientific understanding and early-stage drug development for rare genetic disorders.\u003c\/p\u003e\n\u003cp\u003eStrategic alliances with other biotech firms, such as the ongoing partnership with Arrowhead Pharmaceuticals for RNAi programs, broaden Sarepta's therapeutic pipeline and access to novel technologies, aiming to diversify its product offerings beyond gene therapy.\u003c\/p\u003e\n\u003cp\u003ePartnerships with patient advocacy groups, including Asociación Distrofia Muscular, are instrumental in driving disease awareness and early genetic testing, directly impacting patient identification and access to treatments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eKey Collaborators (Examples)\u003c\/th\u003e\n\u003cth\u003eImpact\/Focus\u003c\/th\u003e\n\u003cth\u003e2023\/2024 Relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Institutions\u003c\/td\u003e\n\u003ctd\u003eNationwide Children's Hospital, Harvard University\u003c\/td\u003e\n\u003ctd\u003eScientific insights, early-stage development\u003c\/td\u003e\n\u003ctd\u003eContinued progress in rare disease research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech\/Pharma Companies\u003c\/td\u003e\n\u003ctd\u003eArrowhead Pharmaceuticals\u003c\/td\u003e\n\u003ctd\u003ePipeline expansion, technology access (RNAi)\u003c\/td\u003e\n\u003ctd\u003eExtension of RNAi program collaboration through 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Manufacturing Organizations (CMOs)\u003c\/td\u003e\n\u003ctd\u003eVarious specialized manufacturers\u003c\/td\u003e\n\u003ctd\u003eTherapy production, capacity scaling\u003c\/td\u003e\n\u003ctd\u003eCrucial for meeting demand for DMD therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Advocacy Groups\u003c\/td\u003e\n\u003ctd\u003eAsociación Distrofia Muscular\u003c\/td\u003e\n\u003ctd\u003eDisease awareness, genetic testing, patient support\u003c\/td\u003e\n\u003ctd\u003eFacilitating patient identification and access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Providers\/Treatment Centers\u003c\/td\u003e\n\u003ctd\u003eSpecialized treatment centers\u003c\/td\u003e\n\u003ctd\u003eTherapy administration, patient monitoring\u003c\/td\u003e\n\u003ctd\u003eExpanding network for Elevidys access in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSarepta Therapeutics' business model focuses on developing and commercializing gene therapies for rare neuromuscular diseases, targeting patients with specific genetic mutations and leveraging a strong R\u0026amp;D pipeline, strategic partnerships, and a patient-centric approach to market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSarepta Therapeutics' Business Model Canvas acts as a pain point reliever by clearly outlining its gene therapy development and commercialization strategy, offering a structured approach to tackling the significant challenges of rare disease drug development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics' core activity revolves around the intensive research and development of precision genetic medicines. This includes pioneering work in RNA-targeted therapies, gene therapy, and gene editing technologies, all aimed at tackling rare neuromuscular diseases.  Their commitment to scientific innovation is evident in their rigorous preclinical studies and multi-phase clinical trials.\u003c\/p\u003e\n\u003cp\u003eA significant portion of Sarepta's resources is dedicated to advancing its pipeline for Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD). In 2024, the company continued to invest heavily in these areas, with ongoing clinical trials for multiple gene therapy candidates, aiming to bring life-changing treatments to patients with high unmet medical needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics' core activities revolve around the meticulous management and execution of clinical trials. This encompasses everything from identifying and enrolling eligible patients to rigorously collecting and analyzing data, all to determine the safety and effectiveness of their novel gene therapies. \u003c\/p\u003e\n\u003cp\u003eThe EMBARK study for ELEVIDYS, a significant milestone for Duchenne muscular dystrophy, exemplifies this. Additionally, ongoing trials for various Limb-girdle muscular dystrophy (LGMD) programs are vital. In 2023, Sarepta reported significant progress in its LGMD pipeline, with multiple trials advancing, underscoring the importance of these activities for future regulatory submissions and expanded market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics’ manufacturing and supply chain management are critical for delivering its complex gene therapies. This involves overseeing internal production facilities and working with contract manufacturing organizations (CMOs) to ensure consistent quality and scalability. For instance, in 2023, Sarepta continued to build out its internal manufacturing capabilities, aiming to bring more production in-house to gain greater control over its supply chain and reduce reliance on external partners.\u003c\/p\u003e\n\u003cp\u003eEnsuring a robust supply chain for these advanced therapies means managing the intricate process of raw material sourcing, specialized production, and global distribution. Sarepta’s strategy includes establishing a reliable network of suppliers and logistics partners capable of handling temperature-sensitive biological products. This focus is paramount as the company aims to meet increasing demand for its approved therapies like Elevidys, which received full FDA approval in June 2023 for Duchenne muscular dystrophy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics' key activities heavily involve navigating the intricate regulatory landscape to bring its gene therapies to market. This includes meticulously preparing and submitting Biologics License Applications (BLAs) to agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).\u003c\/p\u003e\n\u003cp\u003eSuccessfully securing approvals is a critical step, as demonstrated by the FDA's accelerated approval of Elevidys (delandistrogene moxeparvovec-rokl) for certain patients with Duchenne muscular dystrophy in June 2023. This process requires ongoing engagement with regulatory bodies, responding to their feedback, and ensuring compliance with all post-market requirements to maintain commercialization.\u003c\/p\u003e\n\u003cp\u003eKey activities in this area include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePreparing and submitting comprehensive regulatory dossiers, such as BLAs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEngaging with health authorities to address queries and provide necessary data.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eManaging post-approval commitments and ensuring ongoing compliance.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMonitoring and adapting to evolving regulatory guidelines and requirements.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics' commercialization efforts focus on making its approved gene therapies available to patients. This includes robust sales and marketing strategies aimed at healthcare providers.  For instance, in 2024, Sarepta continued to build its commercial infrastructure to support the rollout of therapies like Elevidys for Duchenne muscular dystrophy.\u003c\/p\u003e\n\u003cp\u003eEnsuring patient access is paramount, involving close collaboration with insurance providers and government payers to secure reimbursement.  This process is critical for high-value treatments, as it directly impacts affordability and uptake.  The company actively engages in discussions with payers to demonstrate the long-term value and clinical benefits of its therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales and Marketing:\u003c\/strong\u003e Building and maintaining a specialized sales force to educate physicians and key opinion leaders on the benefits and administration of Sarepta's therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayer Engagement:\u003c\/strong\u003e Negotiating with insurance companies and government health programs to establish favorable reimbursement policies and patient access programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Support Programs:\u003c\/strong\u003e Developing and managing programs that assist patients and their families with navigating the complexities of treatment, including financial assistance and logistical support.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Education:\u003c\/strong\u003e Conducting broad educational campaigns to raise awareness about Duchenne muscular dystrophy and the potential of gene therapy among the medical community and patient advocacy groups.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePioneering Gene Therapy Development and Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics' key activities center on the advancement of its gene therapy pipeline, particularly for Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD). This involves continuous investment in research, preclinical studies, and multi-phase clinical trials to bring innovative treatments to patients with rare diseases.\u003c\/p\u003e\n\u003cp\u003eManufacturing and supply chain management are crucial for Sarepta, ensuring the quality and scalability of its complex gene therapies. The company focuses on building internal capabilities and partnering with CMOs to meet growing demand, as seen with the commercialization of Elevidys.\u003c\/p\u003e\n\u003cp\u003eNavigating regulatory pathways is a core function, involving the submission of BLAs and ongoing engagement with agencies like the FDA. Securing approvals, such as the full FDA approval for Elevidys in June 2023, is vital for market access.\u003c\/p\u003e\n\u003cp\u003eCommercialization activities include targeted sales and marketing to healthcare providers and payer engagement to ensure patient access and reimbursement for its therapies. In 2024, Sarepta continued to expand its commercial infrastructure to support its growing portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2023\/2024 Highlights\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003ePioneering gene therapies for rare neuromuscular diseases.\u003c\/td\u003e\n\u003ctd\u003eContinued investment in DMD and LGMD pipeline, advancing multiple gene therapy candidates.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing \u0026amp; Supply Chain\u003c\/td\u003e\n\u003ctd\u003eEnsuring quality and scalability of gene therapies.\u003c\/td\u003e\n\u003ctd\u003eBuilding internal manufacturing capabilities; managing supply for Elevidys.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eSecuring approvals from health authorities.\u003c\/td\u003e\n\u003ctd\u003eFull FDA approval for Elevidys in June 2023; ongoing engagement with global regulatory bodies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eMaking therapies accessible to patients.\u003c\/td\u003e\n\u003ctd\u003eExpanding commercial infrastructure; payer negotiations for reimbursement in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Sarepta Therapeutics Business Model Canvas preview you are viewing is the actual document you will receive upon purchase. This means the structure, content, and formatting are identical to the final deliverable, offering complete transparency. You'll gain immediate access to this same comprehensive analysis, ready for your strategic planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611366703481,"sku":"sarepta-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sarepta-business-model-canvas.png?v=1754756218","url":"https:\/\/matrixbcg.com\/products\/sarepta-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}